Treatment Options for Anemia, Taking Risks Into Consideration: Erythropoiesis-Stimulating Agents Versus Transfusions

Oncologist - United States
doi 10.1634/theoncologist.13-s3-27
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Anemia Treatment With Q2W Darbepoetin Alfa in Patients With Chronic Kidney Disease Naïve to Erythropoiesis-Stimulating Agents

Current Medical Research and Opinion
Medicine
2008English

PCN34 Cost Analysis of Anemia Treatment With Erythropoiesis-Stimulating Agents (ESAs) in Cancer Patients Receiving Chemotherapy in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update

Journal of Oncology Practice
Health PolicyOncology
2019English

Managing Chemotherapy Induced Anemia With Darbepoetin Alfa and Other Erythropoiesis Stimulating Agents: A Nurse's Perspective

Nursing: Research and Reviews
2013English

On Stimulating Curiosity and Taking Intellectual Risks

Human Resource Development Review
Human Resource ManagementOrganizational Behavior
2011English

Effects of Anemia Correction by Erythropoiesis-Stimulating Agents on Cardiovascular Function in Non-Dialysis Patients With Chronic Kidney Disease

International Heart Journal
MedicineCardiovascular MedicineCardiology
2012English

DGI-043 Increased Cost of Erythropoiesis-Stimulating Agents in Some Special Situations

European Journal of Hospital Pharmacy: Science and Practice
Pharmacy
2013English

Association Between High-Dose Erythropoiesis-Stimulating Agents, Inflammatory Biomarkers, and Soluble Erythropoietin Receptors

BMC Nephrology
Nephrology
2011English

Intravenous Iron Versus Oral Iron Versus No Iron With or Without Erythropoiesis- Stimulating Agents (ESA) for Cancer Patients With Anaemia: A Systematic Review and Network Meta-Analysis

Cochrane Database of Systematic Reviews
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy